FDA (CDER)
GUIDANCE FINAL
Physicochemical and Structural (Q3) Characterization of Topical Drug Products Submitted in ANDAs
Published: 3/17/2026Detected: 3/20/2026
Summary preview
Clarifies expectations for Q3 (physicochemical and structural) characterization submissions for topical drug products in ANDAs, emphasizing alignment with quality/CMC demonstration needs rather than relying on…
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountdermatology
manufacturing
quality
#ANDA
#topical drug products
#Q3 characterization
#physicochemical characterization
#structural characterization
Official Source Document Source Verified
Access the original document directly from FDA CDER.
More from FDA (CDER)
- E14 and S7B Clinical and Nonclinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential--Questions and Answers (R1): Guidance for Industry10/30/2026
- Submitting Clinical Trial Data to Evaluate the Ability to Operate a Motor Vehicle10/20/2026
- Regulatory Considerations for Prescription Drug Use-Related Software10/20/2026
- Safety Reporting Requirements for INDs and BA/BE Studies: Guidance for Industry and Investigators10/19/2026
- Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products: Questions and Answers10/9/2026